The impact of cannabis and cannabinoids for medical conditions on health-related quality of life: A systematic review and meta-analysis

Drug and Alcohol Dependence

Volumn 174, Issue , 2017, Pages 80-90

  Goldenberg, Matthew ^a   Reid, Mark William ^a   IsHak, Waguih William ^a,b   Danovitch, Itai ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cannabinoids; Cannabis; HRQOL; Marijuana; QOL; Quality of life

Indexed keywords

CANNABINOID; CANNABIS; DEXANABINOL; DIHYDROCODEINE; DRONABINOL; GABAPENTIN; NABILONE; NABIXIMOLS; ANALGESIC AGENT; MEDICAL CANNABIS;

ANOREXIA; CACHEXIA; CANCER PAIN; CHRONIC PAIN; FIBROMYALGIA; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATORY BOWEL DISEASE; META ANALYSIS; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; MUSCLE CRAMP; NEUROPATHIC PAIN; PAIN; PATIENT-REPORTED OUTCOME; PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TRAUMATIC BRAIN INJURY; CROSS-SECTIONAL STUDY; HIV INFECTIONS; INFLAMMATORY BOWEL DISEASES; THERAPY;

ANALGESICS; CROSS-SECTIONAL STUDIES; HIV INFECTIONS; HUMANS; INFLAMMATORY BOWEL DISEASES; MEDICAL MARIJUANA; MULTIPLE SCLEROSIS; PAIN; QUALITY OF LIFE; THERAPEUTICS;

EID: 85015640274     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2016.12.030     Document Type: Review

References (39)

1. Aggarwal, S.K., Carter, G.T., Sullivan, M.D., Zumbrunnen, C., Morrill, R., Mayer, J.D., Prospectively surveying health-related quality of life and symptom relief in a lot-based sample of medical cannabis-using patients in urban Washington State reveals managed chronic illness and debility. Am. J. Hosp. Palliat. Care 30 (2013), 523–531, 10.1177/1049909112454215.
2. Bestard, J.A., Toth, C.C., An open-label comparison of nabilone and gabapentin as adjuvant therapy or monotherapy in the management of neuropathic pain in patients with peripheral neuropathy. Pain Pract. 11 (2011), 353–368, 10.1111/j.1533-2500.2010.00427.x.
3. Cannabis-In-Cachexia-Study-Group, Strasser, F., Luftner, D., Possinger, K., Ernst, G., Ruhstaller, T., Meissner, W., Ko, Y.D., Schnelle, M., Cerny, T., Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J. Clin. Oncol. 24 (2006), 3394–3400, 10.1200/JCO.2005.05.1847.
4. Cerda, M., Wall, M., Keyes, K.M., Galea, S., Hasin, D., Medical marijuana laws in 50 states: investigating the relationship between state legalization of medical marijuana and marijuana use, abuse and dependence. Drug Alcohol Depend. 120 (2012), 22–27, 10.1016/j.drugalcdep.2011.06.011.
5. Cohen, J., Statistical Power Analysis For The Behavioral Sciences. 2nd ed., 1988, L. Erlbaum Associates, Hillsdale, N.J.
6. Collin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., Powell, K., Notcutt, W., O'Leary, C., Ratcliffe, S., Nováková, I., Zapletalova, O., Piková, J., Ambler, Z., A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol. Res. 32 (2010), 451–459, 10.1179/016164109x12590518685660.
7. Fiz, J., Duran, M., Capella, D., Carbonell, J., Farre, M., Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life. PLoS One, 60, 2011, e18440, 10.1371/journal.pone.0018440.
8. Flachenecker, P., Henze, T., Zettl, U.K., Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice. Eur. Neurol. 72 (2014), 95–102, 10.1159/000360285.
9. Flachenecker, P., Henze, T., Zettl, U.K., Nabiximols (THC/CBD oromucosal spray, Sativex(R)) in clinical practice-results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity. Eur. Neurol. 71 (2014), 271–279, 10.1159/000357427.
10. Frank, B., Serpell, M.G., Hughes, J., Matthews, J.N., Kapur, D., Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ 336 (2008), 199–201, 10.1136/bmj.39429.619653.80.
11. Haberstick, B.C., Young, S.E., Zeiger, J.S., Lessem, J.M., Hewitt, J.K., Hopfer, C.J., Prevalence and correlates of alcohol and cannabis use disorders in the United States: results from the national longitudinal study of adolescent health. Drug Alcohol Depend. 136 (2014), 158–161, 10.1016/j.drugalcdep.2013.11.022.
12. Hedges, L., Vevea, J., Fixed- and random-effects models in meta-analysis. Psychol. Methods 3 (1998), 486–504.
13. Higgins, J.P.T., Green, S., Cochrane Collaboration, Cochrane Handbook For Systematic Reviews Of Interventions. 2008, Wiley-Blackwell Chichester, England; Hoboken, NJ.
14. Higgins, J.P., Altman, D.G., Gotzsche, P.C., Juni, P., Moher, D., Oxman, A.D., Savović, J., Schulz, K.F., Weeks, L., Sterne, J.A.C., Cochrane Statistical Methods Group, The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ, 343, 2011, d5928, 10.1136/bmj.d5928.
15. Hill, K.P., Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. JAMA 313 (2015), 2474–2483, 10.1001/jama.2015.6199.
16. Johnson, J.R., Burnell-Nugent, M., Lossignol, D., Ganae-Motan, E.D., Potts, R., Fallon, M.T., Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J. Pain Symptom Manage. 39 (2010), 167–179, 10.1016/j.jpainsymman.2009.06.008.
17. Johnson, J.R., Lossignol, D., Burnell-Nugent, M., Fallon, M.T., An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J. Pain Symptom Manage. 46 (2013), 207–218, 10.1016/j.jpainsymman.2012.07.014.
18. Korthuis, P.T., Zephyrin, L.C., Fleishman, J.A., Saha, S., Josephs, J.S., McGrath, M.M., Hellinger, J., Gebo, K.A., Research Network, H.I.V., Health-related quality of life in HIV-infected patients: the role of substance use. Aids Patient Care STDS 22 (2008), 859–867, 10.1089/apc.2008.0005.
19. Kramer, J.L., Medical marijuana for cancer. C.A. Cancer J. Clin. 65 (2015), 109–122, 10.3322/caac.21260.
20. Lahat, A., Lang, A., Ben-Horin, S., Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: a pilot prospective study. Digestion 85 (2012), 1–8, 10.1159/000332079.
21. Liberati, A., Altman, D.G., Tetzlaff, J., Mulrow, C., Gotzsche, P.C., Ioannidis, J.P., Clarke, M., Devereaux, P.J., Kleijnen, J., Moher, D., The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann. Intern. Med. 151 (2009), W65–94.
22. Ligresti, A., De Petrocellis, L., Di Marzo, V., From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology. Physiol. Rev. 96 (2016), 1593–1659, 10.1152/physrev.00002.2016.
23. Maas, A.I., Murray, G., Henney, H., Kassem, 3rd, Legrand, N., Mangelus, V., Muizelaar, M., Stocchetti, J.P., Knoller, N., Pharmos, N., TBI Investigators, Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial. Lancet Neurol. 5 (2006), 38–45, 10.1016/s1474-4422(05)70253-2.
24. Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Group, P., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J. Clin. Epidemiol. 62 (2009), 1006–1012, 10.1016/j.jclinepi.2009.06.005.
25. NIH: National Cancer Institute, Dexanabinol. 2004, NIH: National Cancer Institute website http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=720043.
26. Novotna, A., Mares, J., Ratcliffe, S., Novakova, I., Vachova, M., Zapletalova, O., Gasperini, C., Pozzilli, C., Cefaro, L., Comi, G., Rossi, P., Ambler, Z., Stelmasiak, Z., Erdmann, A., Montalban, X., Klimek, A., Davies, P., Sativex Spasticity Study Group, A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex((R))), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur. J. Neurol. 18 (2011), 1122–1131, 10.1111/j.1468-1331.2010.03328.x.
27. Pini, L.A., Guerzoni, S., Cainazzo, M.M., Ferrari, A., Sarchielli, P., Tiraferri, I., Ciccarese, M., Zappaterra, M., Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial. J. Headache Pain. 13 (2012), 677–684, 10.1007/s10194-012-0490-1.
28. Portenoy, R.K., Ganae-Motan, E.D., Allende, S., Yanagihara, R., Shaiova, L., Weinstein, S., McQuade, R., Wright, S., Fallon, M.T., Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J. Pain 13 (2012), 438–449, 10.1016/j.jpain.2012.01.003.
29. Reinarman, C., Nunberg, H., Lanthier, F., Heddleston, T., Who are medical marijuana patients? Population characteristics from nine California assessment clinics. J. Psychoactive Drugs 43 (2011), 128–135, 10.1080/02791072.2011.587700.
30. Ryan-Ibarra, S., Induni, M., Ewing, D., Prevalence of medical marijuana use in California, 2012. Drug Alcohol Rev. 34 (2015), 141–146, 10.1111/dar.12207.
31. Schuermeyer, J., Salomonsen-Sautel, S., Price, R.K., Balan, S., Thurstone, C., Min, S.J., Sakai, J.T., Temporal trends in marijuana attitudes, availability and use in Colorado compared to non-medical marijuana states: 2003-11. Drug Alcohol Depend. 140 (2014), 145–155, 10.1016/j.drugalcdep.2014.04.016.
32. Sherbourne, C.D., Hays, R.D., Fleishman, J.A., Vitiello, B., Magruder, K.M., Bing, E.G., McCaffrey, D., Burnam, A., Longshore, D., Eggan, F., Bozzette, S.A., Shapiro, M.F., Impact of psychiatric conditions on health-related quality of life in persons with HIV infection. Am. J. Psychiatry 157 (2000), 248–254.
33. Stith, S.S., Vigil, J.M., Federal barriers to cannabis research. Science, 352, 2016, 1182, 10.1126/science.aaf7450.
34. Storr, M., Devlin, S., Kaplan, G.G., Panaccione, R., Andrews, C.N., Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn's disease. Inflamm. Bowel Dis. 20 (2014), 472–480, 10.1097/01 (MIB.0000440982.79036. d6).
35. Svendsen, K.B., Jensen, T.S., Bach, F.W., Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ, 329, 2004, 253, 10.1136/bmj.38149.566979.AE.
36. Ware, J.E., Kosinski, M., Keller, S.D., SF-36 Physical and Mental Health Summary Scales: A Users' Manual. 1994.
37. Ware, M.A., Wang, T., Shapiro, S., Robinson, A., Ducruet, T., Huynh, T., Gamsa, A., Bennett, G.J., Collet, J.P., Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ 182 (2010), E694–E701, 10.1503/cmaj.091414.
38. Weber, M., Goldman, B., Truniger, S., Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial. J. Neurol. Neurosurg. Psychiatry 81 (2010), 1135–1140, 10.1136/jnnp.2009.200642.
39. Whiting, P.F., Wolff, R.F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A.V., Keurentjes, J.C., Lang, S., Misso, K., Ryder, S., Schmidlkofer, S., Westwood, M., Kleijnen, J., Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 313 (2015), 2456–2473, 10.1001/jama.2015.6358.